Cancer neovascularization and proinflammatory microenvironments

Current Cancer Drug Targets

Volumn 8, Issue 4, 2008, Pages 253-265

  Furuya, Mitsuko ^a   Yonemitsu, Yoshikazu ^b  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Chemokines; Endothelial cells; Endothelial progenitor cells; Hematopoietic cells; Mesenchymal cells; Neovascularization; Tumor

Indexed keywords

ALPHA CHEMOKINE; BASIC FIBROBLAST GROWTH FACTOR; BETA CHEMOKINE; BEVACIZUMAB; GAMMA INTERFERON; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; AUTOCRINE EFFECT; CANCER STEM CELL; ENDOTHELIUM CELL; FIBROBLAST; HEMATOPOIETIC CELL; HUMAN; MESENCHYME CELL; METASTASIS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANTIBODIES, MONOCLONAL; HUMANS; INFLAMMATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 45849117953     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908784533481     Document Type: Review

References (163)

1. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
2. Dvorak, H. F.; Nagy, J. A.; Feng, D.; Brown, L. F.; Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 1999, 237, 97-132.
3. Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002, 20, 4368-4380.
4. Hida, K.; Hida, Y.; Amin, D. N.; Flint, A. F.; Panigrahy, D.; Morton, C. C.; Klagsbrun, M. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 2004, 64, 8249-8255.
5. Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der Zee, R.; Li, T.; Witzenbichler, B.; Schatteman, G.; Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275, 964-967.
6. Lyden, D.; Hattori, K.; Dias, S.; Costa, C.; Blaikie, P.; Butros, L.; Chadburn, A.; Heissig, B.; Marks, W.; Witte, L.; Wu, Y.; Hicklin, D.; Zhu, Z.; Hackett, N. R.; Crystal, R. G.; Moore, M. A.; Hajjar, K. A.; Manova, K.; Benezra, R.; Rafii, S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7, 1194-1201.
7. Hattori, K.; Heissig, B.; Wu, Y.; Dias, S.; Tejada, R.; Ferris, B.; Hicklin, D. J.; Zhu, Z.; Bohlen, P.; Witte, L.; Hendrikx, J.; Hackett, N. R.; Crystal, R. G.; Moore, M. A.; Werb, Z.; Lyden, D.; Rafii, S. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 2002, 8, 841-849.
8. Bruno, S.; Bussolati, B.; Grange, C.; Collino, F.; Graziano, M. E.; Ferrando, U.; Camussi, G. CD133+ renal progenitor cells contribute to tumor angiogenesis. Am. J. Pathol. 2006, 169, 2223-2235.
9. Zengin, E.; Chalajour, F.; Gehling, U. M.; Ito, W. D.; Treede, H.; Lauke, H.; Weil, J.; Reichenspurner, H.; Kilic, N.; Ergün, S. Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development 2006, 133, 1543-1551.
10. Oswald, J.; Boxberger, S.; Jørgensen, B.; Feldmann, S.; Ehninger, G.; Bornhäuser, M.; Werner, C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004, 22, 377-384.
11. Elsheikh, E.; Uzunel, M.; He, Z.; Holgersson, J.; Nowak, G.; Sumitran-Holgersson, S. Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity Blood 2005, 106, 2347-2355.
12. Kuwana, M.; Okazaki, Y.; Kodama, H.; Satoh, T.; Kawakami, Y.; Ikeda, Y. Endothelial differentiation potential of human monocyte-derived multipotential cells. Stem Cells 2006, 24, 2733-2743.
13. th ed., Garland Publishing: New York, 2001, pp. 571-572.
14. Lewis, C. E.; Pollard, J. W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66, 605-612.
15. Mantovani, A.; Schioppa, T.; Porta, C.; Allavena, P.; Sica, A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006, 25, 315-322.
16. Sivakumar, B.; Harry, L. E.; Paleolog, E. M. Modulating angiogenesis: more vs less. JAMA 2004, 292, 972-977.
17. Verheul, H. M.; Pinedo, H. M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 2007, 7, 475-485.
18. St Croix, B.; Rago, C.; Velculescu, V.; Traverso, G.; Romans, K. E.; Montgomery, E.; Lal, A.; Riggins, G. J.; Lengauer, C.; Vogelstein, B.; Kinzler, K. W. Genes expressed in human tumor endothelium. Science 2000, 289, 1197-1202.
19. Shih, S. C.; Robinson, G. S.; Perruzzi, C. A.; Calvo, A.; Desai, K.; Green, J. E.; Ali, I. U.; Smith, L. E.; Senger, D. R. Molecular profiling of angiogenesis markers. Am. J. Pathol. 2002, 161, 35-41.
20. Mutuberria, R.; Satijn, S.; Huijbers, A.; Van Der Linden, E.; Lichtenbeld, H.; Chames, P.; Arends, J. W.; Hoogenboom, H. R. Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries. J. Immunol. Methods 2004, 287, 31-47.
21. Oh, P.; Li, Y.; Yu, J.; Durr, E.; Krasinska, K. M.; Carver, L. A.; Testa, J. E.; Schnitzer, J. E. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004, 429, 629-635.
22. Seaman, S.; Stevens, J.; Yang, M. Y.; Logsdon, D.; Graff-Cherry, C.; St Croix, B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007, 11, 539-554.
23. Wang, J. H.; Wu, Q. D.; Bouchier-Hayes, D.; Redmond, H. P. Hypoxia upregulates Bcl-2 expression and suppresses interferon-gamma induced antiangiogenic activity in human tumor derived endothelial cells. Cancer 2002, 94, 2745-2755.
24. Bussolati, B.; Deambrosis, I.; Russo, S.; Deregibus, M. C.; Camussi, G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J. 2003, 17, 1159-1161.
25. Carson-Walter, E. B.; Watkins, D. N.; Nanda, A.; Vogelstein, B.; Kinzler, K. W.; St Croix, B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001, 61, 6649-6655.
26. Duff, S. E.; Li, C.; Garland, J. M.; Kumar, S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003, 17, 984-992.
27. Sullivan, D. C.; Huminiecki, L.; Moore, J. W.; Boyle, J. J.; Poulsom, R.; Creamer, D.; Barker, J.; Bicknell, R. EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J. Biol. Chem. 2003, 278, 47079-47088.
28. Fonsatti, E.; Maio, M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J. Transl. Med. 2004, 2, 18.
29. Marchand, F.; Perretti, M.; McMahon, S. B. Role of the immune system in chronic pain. Nat. Rev. Neurosci. 2005, 6, 521-532.
30. Sun, Y.; Chen, J. H.; Fu, Y. Immunotherapy with agonistic anti-CD137: two sides of a coin. Cell Mol. Immunol. 2004, 1, 31-36.
31. Uno, T.; Takeda, K.; Kojima, Y.; Yoshizawa, H.; Akiba, H.; Mittler, R. S.; Gejyo, F.; Okumura, K.; Yagita, H.,; Smyth, M. J. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 2006, 12, 693-698.
32. Tamada, K; Chen, L. Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol. Immunother. 2006, 55, 355-362.
33. Broll, K.; Richter, G.; Pauly, S.; Hofstaedter, F.; Schwarz, H. CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am. J. Clin. Pathol. 2001, 115, 543-549.
34. Castriconi, R.; Dondero, A.; Augugliaro, R.; Cantoni, C.; Carnemolla, B.; Sementa, A. R.; Negri, F.; Conte, R.; Corrias, M. V.; Moretta, L.; Moretta, A.; Bottino, C. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc. Natl. Acad. Sci. USA 2004, 101, 12640-12645.
35. Sun, Y.; Wang, Y.; Zhao, J.; Gu, M.; Giscombe, R.; Lefvert, A. K.; Wang, X. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006, 53, 143-151.
36. Castriconi, R.; Dondero, A.; Negri, F.; Bellora, F.; Nozza, P.; Carnemolla, B.; Raso, A.; Moretta, L.; Moretta, A.; Bottino, C. Both CD133(+) and CD133(-) medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity. Eur. J. Immunol. 2007, 37, 3190-3196.
37. Risau, W. Mechanisms of angiogenesis. Nature 1997, 386, 671-674.
38. Patterson, C. The Ponzo effect: endothelial progenitor cells appear on the horizon Circulation 2003, 107, 2995-2997.
39. Takahashi, T.; Kalka, C.; Masuda, H.; Chen, D.; Silver, M.; Kearney, M.; Magner, M.; Isner, J. M.; Asahara, T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 1999, 5, 434-438.
40. Aicher, A.; Brenner, W.; Zuhayra, M.; Badorff, C.; Massoudi, S.; Assmus, B.; Eckey, T.; Henze, E.; Zeiher, A. M.; Dimmeler, S. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 2003, 107, 2134-2139.
41. Rafii, S.; Lyden, D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 2003, 9, 702-712.
42. Beerepoot, L. V.; Mehra, N.; Vermaat, J. S.; Zonnenberg, B. A.; Gebbink, M. F.; Voest, E. E. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann. Oncol. 2004, 15, 139-145
43. Tepper, O. M.; Capla, J. M.; Galiano, R. D.; Ceradini, D. J.; Callaghan, M. J.; Kleinman, M. E.; Gurtner, G. C. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 2005, 105, 1068-1077.
44. Fürstenberger, G.; von Moos, R.; Lucas, R.; Thürlimann, B.; Senn, H. J.; Hamacher, J.; Boneberg, E. M. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br. J. Cancer 2006, 94, 524-531.
45. Mancuso, P.; Colleoni, M.; Calleri, A.; Orlando, L.; Maisonneuve, P.; Pruneri, G.; Agliano, A.; Goldhirsch, A.; Shaked, Y.; Kerbel, R. S.; Bertolini, F. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006, 108, 452-459.
46. Bertolini, F.; Shaked, Y.; Mancuso, P.; Kerbel, R. S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 2006, 6, 835-845.
47. Murayama, T.; Tepper, O. M.; Silver, M.; Ma, H.; Losordo, D. W.; Isner, J. M.; Asahara, T.; Kalka, C. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp. Hematol. 2002, 30, 967-972.
48. Vajkoczy, P.; Blum, S.; Lamparter, M.; Mailhammer, R.; Erber, R.; Engelhardt, B.; Vestweber, D.; Hatzopoulos, A. K. Multistep nature of microvascular recruitment of ex vivo-expanded embryonic endothelial progenitor cells during tumor angiogenesis. J. Exp. Med. 2003, 197, 1755-1765.
49. Li, H.; Gerald, W. L.; Benezra, R. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res. 2004, 64, 6137-6143.
50. Rehman, J.; Li, J.; Orschell, C. M.; March, K. L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003, 107, 1164-1169.
51. Zhao, Y.; Glesne, D.; Huberman, E. A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc. Natl. Acad. Sci. USA 2003, 100, 2426-2431.
52. Conejo-Garcia, J. R.; Benencia, F.; Courreges, M. C.; Kang, E.; Mohamed-Hadley, A.; Buckanovich, R. J.; Holtz, D. O.; Jenkins, A.; Na, H.; Zhang, L.; Wagner, D. S.; Katsaros, D.; Caroll, R.; Coukos, G. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 2004, 10, 950-958.
53. Yang, L.; DeBusk, L. M.; Fukuda, K.; Fingleton, B.; Green-Jarvis, B.; Shyr, Y.; Matrisian, L. M.; Carbone, D. P.; Lin, P. C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004, 6, 409-421.
54. Pan, P.Y.; Wang, G. X.; Yin, B.; Ozao, J.; Ku, T.; Divino, C. M.; Chen, S. H. Reversion of immune tolerance in advanced malignancy: modulation of myeloid derived suppressor cell development by blockade of SCF function. Blood 2008, 111(1), 219-228.
55. Peters, B. A.; Diaz, L. A.; Polyak, K.; Meszler, L.; Romans, K.; Guinan, E. C.; Antin, J. H.; Myerson, D.; Hamilton, S. R.; Vogelstein, B.; Kinzler, K. W.; Lengauer, C. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 2005, 11, 261-262.
56. Fernandez Pujol, B.; Lucibello, F. C.; Gehling, U. M.; Lindemann, K.; Weidner, N.; Zuzarte, M. L.; Adamkiewicz, J.; Elsässer, H. P.; Müller, R.; Havemann, K. Endothelial-like cells derived from human CD14 positive monocytes. Differentiation 2000, 65, 287-300
57. Schmeisser, A.; Garlichs, C. D.; Zhang, H.; Eskafi, S.; Graffy, C.; Ludwig, J.; Strasser, R. H.; Daniel, W. G. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc. Res. 2001, 49, 671-680.
58. Schatteman, G. C.; Dunnwald, M.; Jiao, C. Biology of bone marrow-derived endothelial cell precursors. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H1-H18.
59. Gallina, G.; Dolcetti, L.; Serafini, P.; De Santo, C.; Marigo, I.; Colombo, M. P.; Basso, G.; Brombacher, F.; Borrello, I.; Zanovello, P.; Bicciato, S.; Bronte, V. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 2006, 116, 2777-2790.
60. Kusmartsev, S; Gabrilovich, D. I. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 2006, 55, 237-245.
61. Serafini, P.; Borrello, I.; Bronte, V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16, 53-65.
62. Grunewald, M.; Avraham, I.; Dor, Y.; Bachar-Lustig, E.; Itin, A.; Jung, S.; Chimenti, S.; Landsman, L.; Abramovitch, R.; Keshet, E. Cell 2006, 124, 175-189.
63. Jin, D. K.; Shido, K.; Kopp, H. G.; Petit, I.; Shmelkov, S. V.; Young, L. M.; Hooper, A. T.; Amano, H.; Avecilla, S. T.; Heissig, B.; Hattori, K.; Zhang, F.; Hicklin, D. J.; Wu, Y.; Zhu, Z.; Dunn, A.; Salari, H.; Werb, Z.; Hackett, N. R.; Crystal, R. G.; Lyden, D.; Rafii, S. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat. Med. 2006, 12, 557-567.
64. Kitamura, T.; Kometani, K.; Hashida, H.; Matsunaga, A.; Miyoshi, H.; Hosogi, H.; Aoki, M.; Oshima, M.; Hattori, M.; Takabayashi, A.; Minato, N.; Taketo M. M. SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat. Genet. 2007, 39, 467-475.
65. Ziegelhoeffer, T.; Fernandez, B.; Kostin, S.; Heil, M.; Voswinckel, R.; Helisch, A.; Schaper, W. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ. Res. 2004, 94, 230-238.
66. O'Neill, T. J.; Wamhoff, B. R.; Owens, G. K.; Skalak, T. C. Mobilization of bone marrow-derived cells enhances the angiogenic response to hypoxia without transdifferentiation into endothelial cells. Circ. Res. 2005, 97, 1027-1035.
67. Udagawa, T.; Puder, M.; Wood, M.; Schaefer, B. C.; D'Amato, R. J. Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J. 2006, 20, 95-102.
68. Rajantie, I.; Ilmonen, M.; Alminaite, A.; Ozerdem, U.; Alitalo, K.; Salven, P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004, 104, 2084-2086.
69. De Palma, M.; Venneri, M. A.; Galli, R.; Sergi, L.; Politi, L. S.; Sampaolesi, M.; Naldini, L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8, 211-226.
70. Bonnet, D.; Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737.
71. Al-Hajj, M.; Wicha, M. S.; Benito-Hernandez, A.; Morrison, S. J.; Clarke, M. F. Prospetive identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3938.
72. Singh, S. K.; Hawkins, C.; Clarke, I. D.; Squire, J. A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M. D.; Dirks, P. B. Identification of human brain tumour initiating cells. Nature 2004, 432, 396-401.
73. Jordan, C. T.; Guzman, M. L.; Noble, M. Cancer stem cells. N. Engl. J. Med. 2006, 355, 1253-1261.
74. Ishikawa, F.; Yoshida, S.; Saito, Y.; Hijikata, A.; Kitamura, H.; Tanaka, S.; Nakamura, R.; Tanaka, T.; Tomiyama, H.; Saito, N.; Fukata, M.; Miyamoto, T.; Lyons, B.; Ohshima, K.; Uchida, N.; Taniguchi, S.; Ohara, O.; Akashi, K.; Harada, M.; Shultz, L. D. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007, 25, 1315-1321.
75. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T. L.; Fuller, C.; Hamner, B.; Oh, E. Y.; Gaber, M. W.; Finklestein, D.; Allen, M.; Frank, A.; Bayazitov, I. T.; Zakharenko, S. S.; Gajjar, A.; Davidoff, A.; Gilbertson, R. J. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11, 69-82.
76. Bao, S.; Wu, Q.; Sathornsumetee, S.; Hao, Y.; Li, Z.; Hjelmeland, A. B.; Shi, Q.; McLendon, R. E.; Bigner, D. D.; Rich, J. N. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006, 66, 7843-7848.
77. Dick, J. E. Breast cancer stem cells revealed. Proc. Natl. Acad. Sci. USA 2003, 100, 3547-3549.
78. Ricci-Vitiani, L.; Lombardi, D. G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445, 111-115.
79. Gilbertson, R. J.; Rich, J. N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 2007, 7, 733-736.
80. Kurose, K.; Gilley, K.; Matsumoto, S.; Watson, P. H.; Zhou, X. P.; Eng, C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet. 2002, 32, 355-357.
81. Ishiguro, K.; Yoshida, T.; Yagishita, H.; Numata, Y.; Okayasu, T. Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas. Gut 2006, 55, 695-702.
82. Orimo, A.; Gupta, P. B.; Sgroi, D. C.; Arenzana-Seisdedos, F.; Delaunay, T.; Naeem, R.; Carey, V. J.; Richardson, A. L.; Weinberg, R. A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121, 335-348.
83. Moinfar, F.; Man, Y. G.; Arnould, L.; Bratthauer, G. L.; Ratschek, M.; Tavassoli, F. A. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res. 2000, 60, 2562-2566
84. Ishii, G.; Ito, T. K.; Aoyagi, K.; Fujimoto, H.; Chiba, H.; Hasebe, T.; Fujii, S.; Nagai, K.; Sasaki, H.; Ochiai, A. Presence of human circulating progenitor cells for cancer stromal fibroblasts in the blood of lung cancer patients. Stem Cells 2007, 25, 1469-1477.
85. Pittenger, M. F.; Mackay, A. M.; Beck, S. C.; Jaiswal, R. K.; Douglas, R.; Mosca, J. D.; Moorman, M. A.; Simonetti, D. W.; Craig, S.; Marshak, D. R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284, 143-147.
86. Ohnishi, S.; Yasuda, T.; Kitamura, S.; Nagaya, N. Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Stem Cells 2007, 25, 1166-1177.
87. Karnoub, A. E.; Dash, A. B.; Vo, A. P.; Sullivan, A.; Brooks, M. W.; Bell, G. W.; Richardson, A. L.; Polyak, K.; Tubo, R.; Weinberg, R. A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 2007, 449, 557-563.
88. Dwyer, R. M.; Potter-Beirne, S. M.; Harrington, K. A.; Lowery, A. J.; Hennessy, E.; Murphy, J. M.; Barry, F. P.; O'Brien, T.; Kerin, M. J. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin. Cancer Res. 2007, 13, 5020-5027.
89. Soucek, L.; Lawlor, E. R.; Soto, D.; Shchors, K.; Swigart, L. B.; Evan, G. I. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007, 13, 1211-1218.
90. Kaplan, R. N.; Riba, R. D.; Zacharoulis, S.; Bramley, A. H.; Vincent, L.; Costa, C.; MacDonald, D. D.; Jin, D. K.; Shido, K.; Kerns, S. A.; Zhu, Z.; Hicklin, D.; Wu, Y.; Port, J. L.; Altorki, N.; Port, E. R.; Ruggero, D.; Shmelkov, S. V.; Jensen, K. K.; Rafii, S.; Lyden, D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438, 820-827.
91. Hiratsuka, S.; Nakamura, K.; Iwai, S.; Murakami, M.; Itoh, T.; Kijima, H.; Shipley, J. M.; Senior, R. M.; Shibuya, M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002, 2, 289-300.
92. Hiratsuka, S.; Watanabe, A.; Aburatani, H.; Maru, Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 2006, 8, 1369-1375.
93. Olaso, E.; Salado, C.; Egilegor, E.; Gutierrez, V.; Santisteban, A.; Sancho-Bru, P.; Friedman, S. L.; Vidal-Vanaclocha, F. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 2003, 37, 674-685.
94. Phillips, R. J.; Burdick, M. D.; Hong, K.; Lutz, M. A.; Murray, L. A.; Xue, Y. Y.; Belperio, J. A.; Keane, M. P.; Strieter, R. M. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 2004, 114, 438-446.
95. Gomperts, B. N; Strieter, R. M. Fibrocytes in lung disease. J. Leukoc. Biol. 2007, 82, 449-456.
96. Ferrara, N.; Carver-Moore, K.; Chen, H.; Dowd, M.; Lu, L.; O'Shea, K. S.; Powell-Braxton, L.; Hillan, K. J.; Moore, M. W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380, 439-442.
97. Ferrara, N.; Chen, H.; Davis-Smyth, T.; Gerber, H. P.; Nguyen, T. N.; Peers, D.; Chisholm V.; Hillan K. J.; Schwall R. H. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 1998, 4, 336-340.
98. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000. 6, 389-395
99. Maynard, S. E.; Min, J. Y.; Merchan, J.; Lim, K. H.; Li, J.; Mondal, S.; Libermann, T. A.; Morgan, J. P.; Sellke, F. W.; Stillman, I. E.; Epstein, F. H.; Sukhatme, V. P.; Karumanchi, S. A. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003, 111, 649-658.
100. Venkatesha, S.; Toporsian, M.; Lam, C.; Hanai, J.; Mammoto, T.; Kim, Y. M.; Bdolah, Y.; Lim, K. H.; Yuan, H. T.; Libermann, T. A.; Stillman, I. E.; Roberts, D.; D'Amore, P. A.; Epstein, F. H.; Sellke, F. W.; Romero, R.; Sukhatme, V. P.; Letarte, M.; Karumanchi, S. A. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 2006, 12, 642-649.
101. Kendall, R. L.; Thomas, K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 1993, 90, 10705-10709.
102. Karumanchi, S. A.; Bdolah, Y. Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. Endocrinology 2004, 145, 4835-4837.
103. Redman, C. W.; Sargent, I. L. Latest advances in understanding preeclampsia. Science 2005, 308, 1592-1594.
104. Gerber, H. P.; Malik, A. K.; Solar, G. P.; Sherman, D.; Liang, X. H.; Meng, G.; Hong, K.; Marsters, J. C.; Ferrara, N. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417, 954-958.
105. Sawano, A.; Takahashi, T.; Yamaguchi, S.; Aonuma, M.; Shibuya, M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ. 1996, 7, 213-221.
106. Lee, S.; Chen, T. T.; Barber, C. L.; Jordan, M. C.; Murdock, J.; Desai, S.; Ferrara, N.; Nagy, A.; Roos, K. P.; Iruela-Arispe, M. L. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130, 691-703.
107. Milstien, S.; Spiegel, S. Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell 2006, 9, 148-150.
108. Dorsam, R. T.; Gutkind, J. S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 2007, 7, 79-94.
109. Visentin, B.; Vekich, J. A.; Sibbald, B. J.; Cavalli, A. L.; Moreno, K. M.; Matteo, R. G.; Garland, W. A.; Lu, Y.; Yu, S.; Hall, H. S.; Kundra, V.; Mills, G. B.; Sabbadini, R. A. Validation of an antisphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006, 9, 225-238.
110. Igarashi, J.; Erwin, P. A.; Dantas, A. P.; Chen, H.; Michel, T. VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors. Proc. Natl. Acad. Sci. USA 2003, 100, 10664-10669.
111. Pitson, S. M.; Xia, P.; Leclercq, T. M.; Moretti, P. A.; Zebol, J. R.; Lynn, H. E.; Wattenberg, B. W.; Vadas, M. A. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J. Exp. Med. 2005, 201, 49-54.
112. Compagni, A.; Wilgenbus, P.; Impagnatiello, M. A.; Cotten, M.; Christofori, G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 2000, 60, 7163-7169.
113. Onimaru, M.; Yonemitsu, Y.; Tanii, M.; Nakagawa, K.; Masaki, I.; Okano, S.; Ishibashi, H.; Shirasuna, K.; Hasegawa, M.; Sueishi, K. Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ. Res. 2002, 91, 923-930.
114. Dong, J.; Grunstein, J.; Tejada, M.; Peale, F.; Frantz, G.; Liang, W. C.; Bai, W.; Yu, L.; Kowalski, J.; Liang, X.; Fuh, G.; Gerber, H. P.; Ferrara, N. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J. 2004, 23, 2800-2810.
115. Benjamin, L. E.; Golijanin, D.; Itin, A.; Pode, D.; Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999, 103, 159-165.
116. Reinmuth, N.; Liu, W.; Jung, Y. D.; Ahmad, S. A.; Shaheen, R. M.; Fan, F.; Bucana, C. D.; McMahon, G.; Gallick, G. E.; Ellis, L. M. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 2001, 15, 1239-1241.
117. Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 2003, 9, 685-693.
118. Gee, M. S.; Procopio, W. N.; Makonnen, S.; Feldman, M. D.; Yeilding, N. M.; Lee, W. M. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am. J. Pathol. 2003, 162, 183-193.
119. Gerhardt, H.; Betsholtz, C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 2003, 314, 15-23.
120. Bergers, G.; Song, S.; Meyer-Morse, N.; Bergsland, E.; Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111, 1287-1295.
121. Tsutsumi, N.; Yonemitsu, Y.; Shikada, Y.; Onimaru, M.; Tanii, M.; Okano, S.; Kaneko, K.; Hasegawa, M.; Hashizume, M.; Maehara, Y.; Sueishi, K. Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis. Circ. Res. 2004, 94, 1186-1194.
122. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315, 1650-1659.
123. Coussens, L. M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860-867.
124. Vicari, A. P.; Caux, C. Chemokines in cancer. Cytokine Growth Factor Rev. 2002. 13, 143-154.
125. Arya, M.; Patel, H. R.; Williamson, M. Chemokines: key players in cancer. Curr. Med. Res. Opin. 2003, 19, 557-564.
126. Ben-Baruch, A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 2006, 25, 357-371.
127. Strieter, R. M.; Polverini, P. J.; Kunkel, S. L.; Arenberg, D. A.; Burdick, M. D.; Kasper, J.; Dzuiba, J.; Van Damme, J.; Walz, A.; Marriott, D. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 1995, 270, 27348-27357.
128. Arenberg, D. A.; Keane, M. P.; DiGiovine, B.; Kunkel, S. L.; Morris, S. B.; Xue, Y. Y.; Burdick, M. D.; Glass, M. C.; Iannettoni, M. D.; Strieter, R. M. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest. 1998, 102, 465-472.
129. Frederick, M. J.; Clayman, G. L. Chemokines in cancer. Expert Rev. Mol. Med. 2001, 2001, 1-18.
130. Romagnani, P.; Annunziato, F.; Lasagni, L.; Lazzeri, E.; Beltrame, C.; Francalanci, M.; Uguccioni, M.; Galli, G.; Cosmi, L.; Maurenzig, L.; Baggiolini, M.; Maggi, E.; Romagnani, S.; Serio, M. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 2001, 107, 53-63.
131. Lasagni, L.; Francalanci, M.; Annunziato, F.; Lazzeri, E.; Giannini, S.; Cosmi, L.; Sagrinati, C.; Mazzinghi, B.; Orlando, C.; Maggi, E.; Marra, F.; Romagnani, S.; Serio, M.; Romagnani, P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 2003, 197, 1537-1549.
132. Salcedo, R.; Resau, J. H.; Halverson, D.; Hudson, E. A.; Dambach, M.; Powell, D.; Wasserman, K.; Oppenheim, J. J. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J. 2000, 14, 2055-2064.
133. Tachibana, K.; Hirota, S.; Iizasa, H.; Yoshida, H.; Kawabata, K.; Kataoka, Y.; Kitamura, Y.; Matsushima, K.; Yoshida, N.; Nishikawa, S.; Kishimoto, T.; Nagasawa, T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393, 591-594.
134. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; Barrera, J. L.; Mohar, A.; Verastegui, E.; Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-56.
135. Helbig, G.; Christopherson, K. W. 2nd.; Bhat-Nakshatri, P.; Kumar, S.; Kishimoto, H.; Miller, K. D.; Broxmeyer, H. E.; Nakshatri, H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem. 2003, 278, 21631-21638.
136. Devine, S. M.; Flomenberg, N.; Vesole, D. H.; Liesveld, J.; Weisdorf, D.; Badel, K.; Calandra, G.; DiPersio, J. F. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 2004, 22, 1095-1102.
137. Broxmeyer, H. E.; Orschell, C. M.; Clapp, D. W.; Hangoc, G.; Cooper, S.; Plett, P. A.; Liles, W. C.; Li, X.; Graham-Evans, B.; Campbell, T. B.; Calandra, G.; Bridger, G.; Dale, D. C.; Srour, E. F. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 2005, 201, 1307-1318.
138. Yasumoto, K.; Koizumi, K.; Kawashima, A.; Saitoh, Y.; Arita, Y.; Shinohara, K.; Minami, T.; Nakayama, T.; Sakurai, H.; Takahashi, Y.; Yoshie, O.; Saiki, I. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res. 2006, 66, 2181-2187.
139. Romagnani, P.; Beltrame, C.; Annunziato, F.; Lasagni, L.; Luconi, M.; Galli, G.; Cosmi, L.; Maggi, E.; Salvadori, M.; Pupilli, C.; Serio, M. Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J. Am. Soc. Nephrol. 1999, 10, 2518-2526.
140. Robledo, M. M.; Bartolome, R. A.; Longo, N.; Rodríguez-Frade, J. M.; Mellado, M.; Longo, I.; van Muijen, G. N.; Sánchez-Mateos, P.; Teixidó, J. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J. Biol. Chem. 2001, 276, 45098-45105.
141. Goldberg-Bittman, L.; Sagi-Assif, O.; Meshel, T.; Nevo, I.; Levy-Nissenbaum, O.; Yron, I.; Witz, I. P.; Ben-Baruch, A. Cellular characteristics of neuroblastoma cells: regulation by the ELR - CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 2005, 29, 105-117.
142. Suyama, T.; Furuya, M.; Nishiyama, M.; Kasuya, Y.; Kimura, S.; Ichikawa, T.; Ueda, T.; Nikaido, T.; Ito, H.; Ishikura, H. Upregulation of IFN-γ-inducible chemokine I-TAC and Mig, and their receptor CXCR3 in human renal cell carcinoma. Cancer 2005, 103, 258-267.
143. Zipin-Roitman, A.; Meshel, T.; Sagi-Assif, O.; Shalmon, B.; Avivi, C.; Pfeffer, R. M.; Witz, I. P.; Ben-Baruch, A. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res. 2007, 67, 3396-3405.
144. Soejima, K.; Rollins, B. J. A functional IFN-gamma-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan. J. Immunol. 2001, 167, 6576-6582.
145. Kawada, K.; Sonoshita, M.; Sakashita, H.; Takabayashi, A.; Yamaoka, Y.; Manabe, T.; Inaba, K.; Minato, N.; Oshima, M.; Taketo, M. M. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res. 2004, 64, 4010-4017.
146. Furuya, M.; Nishiyama, M.; Kasuya, Y.; Kimura, S.; Ishikura, H. Pathophysiology of tumor neovascularization. Vasc. Health Risk Manag. 2005, 1, 277-290.
147. Bukowski, R. M.; Rayman, P.; Molto, L.; Tannenbaum, C.S.; Olencki, T.; Peereboom, D.; Tubbs, R.; McLain, D.; Budd, G. T.; Griffin, T.; Novick, A.; Hamilton, T. A.; Finke, J. Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. Clin. Cancer Res. 1999, 5, 2780-2789.
148. Portielje, J. E.; Lamers, C. H.; Kruit, W. H.; Sparreboom, A.; Bolhuis, R. L.; Stoter, G.; Huber, C.; Gratama, J. W. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin. Cancer Res. 2003, 9, 76-83.
149. Salcedo, R.; Ponce, M. L.; Young, H. A.; Wasserman, K.; Ward, J. M.; Kleinman, H. K.; Oppenheim, J. J.; Murphy, W. J. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96, 34-40.
150. Hwang, J.; Kim, C. W.; Son, K. N.; Han, K. Y.; Lee, K. H.; Kleinman, H. K.; Ko, J.; Na, D. S.; Kwon, B. S.; Gho, Y. S.; Kim, J. Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo. FEBS Lett. 2004, 570, 47-51.
151. Son, K. N.; Hwang, J.; Kwon, B. S.; Kim, J. Human CC chemokine CCL23 enhances expression of matrix metalloproteinase-2 and invasion of vascular endothelial cells. Biochem. Biophys. Res. Commun. 2006, 340, 498-504.
152. Bernardini, G.; Ribatti, D.; Spinetti, G.; Morbidelli, L.; Ziche, M.; Santoni, A.; Capogrossi, M. C.; Napolitano, M. Analysis of the role of chemokines in angiogenesis. J. Immunol. Methods 2003, 273, 83-101.
153. Van Damme, J.; Struyf, S.; Opdenakker, G. Chemokine-protease interactions in cancer. Semin. Cancer Biol. 2004, 14, 201-208.
154. Saji, H.; Koike, M.; Yamori, T.; Saji, S.; Seiki, M.; Matsushima, K.; Toi, M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001, 92, 1085-1091.
155. Kuroda, T.; Kitadai, Y.; Tanaka, S.; Yang, X.; Mukaida, N.; Yoshihara, M.; Chayama, K. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin. Cancer Res. 2005, 11, 7629-7636.
156. Springael, J. Y.; Urizar, E.; Parmentier, M. Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev. 2005, 16, 611-623.
157. Wang, J.; He, L.; Combs, C. A.; Roderiquez, G.; Norcross, M. A. Dimerization of CXCR4 in living malignant cells: control of cell migration by a synthetic peptide that reduces homologous CXCR4 interactions. Mol. Cancer Ther. 2006, 5, 2474-2483.
158. Mellado, M.; Rodriguez-Frade, J. M.; Vila-Coro, A. J.; Fernandez, S.; Martin de Ana, A.; Jones, D. R.; Toran, J. L.; Martinez-A, C. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J. 2001, 20, 2497-507.
159. El-Asmar, L.; Springael, J. Y.; Ballet, S.; Andrieu, E. U.; Vassart, G.; Parmentier, M. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol. Pharmacol. 2005, 67, 460-469.
160. Springael, J. Y.; Le Minh, P. N.; Urizar, E.; Costagliola, S.; Vassart, G.; Parmentier, M. Allosteric modulation of binding properties between units of chemokine receptor homo- and heterooligomers. Mol. Pharmacol. 2006, 69, 1652-1661.
161. Sievers, E. L.; Larson, R. A.; Stadtmauer, E. A.; Estey, E.; Löwenberg, B.; Dombret, H.; Karanes, C.; Theobald, M.; Bennett, J. M.; Sherman, M. L.; Berger, M. S.; Eten, C. B.; Loken, M. R.; van Dongen, J. J.; Bernstein, I. D.; Appelbaum, F. R. Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 2001, 19, 3244-3254.
162. Kell, W. J.; Burnett, A. K.; Chopra, R.; Yin, J. A.; Clark, R. E.; Rohatiner, A.; Culligan, D.; Hunter, A.; Prentice, A. G.; Milligan, D. W. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003, 102, 4277-4283.
163. Taussig, D. C.; Pearce, D. J.; Simpson, C.; Rohatiner, A. Z.; Lister, T. A.; Kelly, G.; Luongo, J. L.; Danet-Desnoyers, G. A.; Bonnet, D. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005, 106, 4086-4092.